These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 32361926)
21. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351 [TBL] [Abstract][Full Text] [Related]
23. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Marinova M; Mücke M; Mahlberg L; Essler M; Cuhls H; Radbruch L; Conrad R; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):38-46. PubMed ID: 28864881 [TBL] [Abstract][Full Text] [Related]
24. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072 [TBL] [Abstract][Full Text] [Related]
25. Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. Kaemmerer D; Twrznik M; Kulkarni HR; Hörsch D; Sehner S; Baum RP; Hommann M; Ann Surg; 2021 Jul; 274(1):e45-e53. PubMed ID: 33030849 [TBL] [Abstract][Full Text] [Related]
26. Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study. Trautwein NF; Hinterleitner C; Kiefer LS; Singer S; Mattern S; Schwenck J; Reischl G; Sipos B; Lauer UM; Dittmann H; Zender L; la Fougère C; Hinterleitner M Clin Nucl Med; 2024 Mar; 49(3):207-214. PubMed ID: 38271237 [TBL] [Abstract][Full Text] [Related]
27. Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours? Sowa-Staszczak A; Pach D; Stefańska A; Tomaszuk M; Lenda-Tracz W; Mikołajczak R; Pawlak D; Chrzan R; Gilis-Januszewska A; Przybylik-Mazurek E; Hubalewska-Dydejczyk A Nucl Med Rev Cent East Eur; 2011; 14(2):73-8. PubMed ID: 22219146 [TBL] [Abstract][Full Text] [Related]
28. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response? van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001 [TBL] [Abstract][Full Text] [Related]
30. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Pfeifer AK; Gregersen T; Grønbæk H; Hansen CP; Müller-Brand J; Herskind Bruun K; Krogh K; Kjær A; Knigge U Neuroendocrinology; 2011; 93(3):189-96. PubMed ID: 21335949 [TBL] [Abstract][Full Text] [Related]
31. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours. Kaewput C; Vinjamuri S Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032 [TBL] [Abstract][Full Text] [Related]
32. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925 [TBL] [Abstract][Full Text] [Related]
33. Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with Parghane RV; Basu S J Nucl Cardiol; 2020 Feb; 27(1):340-341. PubMed ID: 30151794 [No Abstract] [Full Text] [Related]
34. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
36. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. Montanier N; Joubert-Zakeyh J; Pétorin C; Montoriol PF; Maqdasy S; Kelly A Medicine (Baltimore); 2017 Feb; 96(6):e6062. PubMed ID: 28178157 [TBL] [Abstract][Full Text] [Related]
37. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy. Gabriel M; Nilica B; Kaiser B; Virgolini IJ J Nucl Med; 2019 Apr; 60(4):524-529. PubMed ID: 30115690 [TBL] [Abstract][Full Text] [Related]